Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Friday

Galectin Therapeutics (NASDAQ:GALT) is anticipated to release its Q3 2026 results on Friday, November 13th. Analysts expect Galectin Therapeutics to post earnings of ($0.05) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.05). On average, analysts expect Galectin Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.23) EPS for the next fiscal year.

Galectin Therapeutics Price Performance

NASDAQ:GALT opened at $3.38 on Wednesday. Galectin Therapeutics has a one year low of $2.03 and a one year high of $7.13. The company has a market cap of $222.61 million, a PE ratio of -7.86 and a beta of 0.53. The firm has a 50-day moving average of $3.72 and a 200-day moving average of $3.22.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GALT shares. Zacks Research raised Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Monday, September 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune regulation. The company’s research is aimed at treating serious chronic diseases in which galectin-3 may contribute to disease progression. Its lead investigational product is belapectin, also known as GR-MD-02, a galectin-3 inhibitor being studied primarily for liver diseases, including nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), and related cirrhosis complications such as portal hypertension.